Poniard Pharmaceuticals to Host Third Quarter 2008 Financial Results Conference Call on October 30.
SOUTH SAN FRANCISCO, Calif., Oct. 23 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on oncology, today announced that it will hold a conference call to discuss the Company's third quarter results and provide a corporate update, including an update on the ongoing development activities for picoplatin,...

Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting.
CALGARY, Oct. 23 /PRNewswire-FirstCall/ -- Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that an abstract entitled "A Phase I Study to Evaluate Systemic Wild-Type Reovirus (REOLYSIN(R)) in Combination with Docetaxel in Patients with Advanced Malignancies" will be available in the November/December issue of the Journal of Immunotherapy,...

Canary Foundation's Dr. Sanjiv Sam Gambhir Elected to the National Academies Institute of Medicine.
SAN JOSE, Calif., Oct. 21 /PRNewswire/ -- Canary Foundation, a nonprofit organization that funds research in early cancer detection, announced that its Scientific Program Director, Dr. Sanjiv Sam Gambhir, has been elected as a new member of the U.S. National Academies Institute of Medicine (IOM). This is one of...

Catechol quinones of estrogens in the initiation of breast, prostate, and other human cancers: keynote lecture.
Estrogens can be converted to electrophilic metabolites, particularly the catechol estrogen-3,4-quinones, estrone (estradiol)-3,4-quinone [E(1)(E(2))-3,4-Q], which react with DNA to form depurinating adducts. These adducts are released from DNA to generate apurinic sites. Error-prone repair of this damage leads to the mutations that initiate breast, prostate, and other types of...

Collegiate Inventors Competition(R) Recognizes Top Student Inventors.
Twelve finalist teams vie for cash prizes awarded for nation's best collegiate inventions AKRON, Ohio, Oct. 22 /PRNewswire/ -- The National Inventors Hall of Fame Foundation today announced the 2008 finalists of its Collegiate Inventors Competition. This year's group of finalists includes undergraduate and graduate students from...

NxStage Announces Streamline(TM) Blood Tubing Set Supply Agreement with Renal Advantage Inc.
LAWRENCE, Mass., Oct. 21 /PRNewswire-FirstCall/ -- NxStage Medical, Inc. , a leading manufacturer of innovative dialysis products, today announced that its Medisystems Division has signed a long-term product supply agreement with Renal Advantage Inc. ("RAI"), the fourth largest provider of dialysis services in the United States. Under the terms...

Vista Partners Updates Coverage on MediciNova Inc. (NASDAQ: MNOV); Maintains $8.50 Price Target.
LOS ANGELES, Oct. 21 /PRNewswire/ -- Vista Partners announced today that it has updated coverage on MediciNova Inc. and maintains its $8.50 price. "MediciNova recently announced positive preliminary data on MN-221. MN-221, if approved, will garner a sizable percentage of the asthma market potentially resulting in hundreds of millions...

Virginia Business Coalition on Health Issues Statement of Support for Hospital Improvement.
Through Reforms Initiated by CMS Organizes Program to Educate Health Care Stakeholders VIRGINIA BEACH, Va., Nov. 19 /PRNewswire/ -- The Virginia Business Coalition on Health (VBCH) announced its continued commitment to improving patient safety through payment reform efforts initiated by the Center for Medicare and Medicaid Services...

DaVita Announces Chief Operating Officer Transition.
EL SEGUNDO, Calif., Oct. 23 /PRNewswire-FirstCall/ -- DaVita Inc. , today announced that Joe Mello will retire as the company's Chief Operating Officer on December 31, 2008. Dennis L. Kogod has been promoted to Chief Operating Officer effective January 1, 2009. Dennis currently serves as DaVita's President -- West,...

Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist.
-- Data Presented at 20th EORTC-NCI-AACR Symposium -- SEATTLE and GENEVA, Oct. 23 /PRNewswire-FirstCall/ -- Researchers from Dendreon Corporation today presented preclinical data on its lead small molecule candidate, D-3263, which targets Trp-p8 (a transmembrane cation channel protein also known as Trp-M8), supporting Trp-p8 as a therapeutic...